COMPARATIVE TRIAL OF ANTIANGINAL DRUGS IN STABLE CORONARY HEART DISEASE


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Nicorandil has a number of advantages over nitrates in treating stable angina pectoris. Thus, enhanced exercise tolerance is accompanied by a significant improvement in the indicators of brain blood supply, better erectile function and quality of life, lower admission rates, and better tolerance. The findings are important in choosing drug therapy policy in this category of patients.

全文:

受限制的访问

作者简介

E. Bulakhova

Omsk State Medical Academy; City Clinical Hospital Four, Omsk

Email: sab.pro@mail.ru

O. Korennova

Omsk State Medical Academy

M. Kondrasheva

City Clinical Hospital Four, Omsk

O. Kamlonko

City Clinical Hospital Four, Omsk

N. Pasechnaya

City Clinical Hospital Four, Omsk

参考

  1. Национальные клинические рекомендации ВНОК, 2010; 369 с.
  2. Ольбинская Л., Морозова Т., Сизова Ж. и др. Фармакотерапия хронических сердечно-сосудистых заболеваний: Руководство для врачей / М.: Медицина, 2006; 386 с.
  3. Horinaka S. Use of nicorandil in cardiovascular disease and its optimization // Drugs. - 2011; 71 (9): 1105-19.
  4. Izumiya Y., Kojima S., Araki S. et al. Long-term use of oral nicorandil stabilizes coronary plaque in patients with stable angina pectoris // Atherosclerosis. - 2011; 214 (2): 415-21.
  5. Kinoshita M., Sakai K. Pharmacology and Therapeutic Effects of Nicorandil. Cardiovacs // Drugs and Therapy. - 1990; 4: 1075-88.
  6. Meany T., Richardson P., Camm A. et al. Exercise capacity after single and twice-daily doses of nicorandil in chronic stable angina pectoris // Am. J. Cardiol. -1989; 63: 66-70.
  7. Okura T., Higaki J., Kurata M. et al. Elevated serum uric acid is an independent predictor for cardiovascular events in patients with severe coronary artery stenosis: Subanalysis of the Japanese Coronary Artery Disease (JCAD) Study // Circ. J. - 2009; 73: 885-91.
  8. Sakamoto T., Kaikita K., Miyamoto S. et al. Effects of nicorandil on endogenous fibrinolytic capacity in patients with coronary artery disease // Circ. J. - 2004; 68: 232-56.
  9. Sakata Y., Nakatani D., Shimizu M. et al. Oral treatment with nicorandil at discharge is associated with reduced mortality after acute myocardial infarction // J. Cardiol. - 2012; 59 (1): 14-21.
  10. Sekiya M., Sato M., Funada J., Ohtani T. et al. Effects of the long-term administration of nicorandil on vascular endothelial function and the progression of arteriosclerosis // J. Cardiovasc. Pharmacol. - 2005; 46 (1): 63-7.

补充文件

附件文件
动作
1. JATS XML

版权所有 © Russkiy Vrach Publishing House, 2013
##common.cookie##